A Study to Evaluate the Drug-drug Interaction Between Telmisartan, Amlodipine and Hydrochlorothiazide

Healthy Clinical Trial

Official title:

A Randomized, Open-label, Single Dose, 3-way Crossover Study to Evaluate the Drug-drugs Interaction Between Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03889145
• Other study ID #: ID-TAH-1301
• Status: Completed
• Phase: Phase 1
• Start date: December 19, 2013
• Est. completion date: February 19, 2014

Study information

• Verified date: March 2019
• Source: IlDong Pharmaceutical Co Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A randomized, open-label, single dose, 3-way crossover study to evaluate the drug-drugs interaction between Telmisartan, Amlodipine and Hydrochlorothiazide in healthy male volunteers

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: February 19, 2014
• Est. primary completion date: February 19, 2014
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 20 Years to 55 Years

Eligibility

Inclusion Criteria:

• Healthy male volunteers aged 20 to 55 years

• Subjects who have 17.5 ~ 30.5 kg/m2 body mass index (BMI) and body weight that is more than 55kg

• Subjects who have no congenital or chronic disease within the last 3 years and have no pathological symptoms or findings as a result of medical examination.

• Suitable subject who is determined by laboratory tests such as hematology tests, blood chemistry, urinalysis test according to the characteristics of the drug and screening tests such as electrocardiography(ECG) test.

• Subject who fully understand the clinical trials after in-depth explanation given prior to the clinical study, decided to join the clinical trials by their will and signed consent form which approved by Chonbuk National University Hospital Institutional Review Board(IRB).

Exclusion Criteria:

• Subjects who have a history of blood, kidneys, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, hepatic, psychiatric, neurological or allergic diseases that is clinically significant (Except untreated asymptomatic seasonal allergies at the time of administration)

• Subjects who have a history of gastrointestinal disease or gastrointestinal surgery which can affect drug absorption.

• Subjects who drink Alcohol > 210g/week within 6 months prior to the screening.

• Subjects who involved in other clinical trials within two months before the first dose medication characters.

• Subjects who show Systolic Blood Pressure =100 or =150 mmHg or Diastolic Blood Pressure =60 or =100 mmHg at screening

• Subjects who had alcohol or drug abuse within one year before the screening

• Subjects who took medication of drug-metabolizing enzymes that are known to significantly induce or inhibit within 30 days

• Subjects who smoke 20 cigarettes or more a day

• Subjects who take medicine within 10 days before the first investigational product administration.

• Subject who done the whole blood donation within two months or component blood donation within 1 month within 1 month prior to the first dosing.

• Subject who can increase risk due to clinical test and administration of drugs or has severe grade / chronic medical, mental condition or abnormal laboratory result that may interfere with the analysis of test results.

• Subjects with serious history of hypersensitivity or allergy to investigational product.

• Subjects with severe hepatic impairment or Gallbladder Disease.

• Subject with hereditary angioedema or a history of angioedema when treated with ACE(Angiotensin-Converting enzyme) inhibitor or ARB(Angiotensin II Receptor Blocker) therapy

• Subjects who take combination medication with aliskiren in Diabetic patient or moderate to severe renal insufficient subjects (glomerular filtration rate<60mL/min/1.73m2)

• Subjects with severe hepatic impairment

• Subjects who have severe aortic stenosis

• Subjects with acute or severe renal failure

• Subjects with hyponatremia or hypokalemia

• Subjects with Addison's disease

• Subjects with hypercalcemia

• Subjects who have galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption

• Subjects who are unwilling or unable to comply with the Lifestyle guidelines described in this protocol

• Subject who are inadequate for this study to participate judged by investigator

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Telmisartan 80mg
Telmisartan 80mg
• Amlodipine10mg
Amlodipine 10mg
• Hydrochlorothiazide
Hydrochlorothiazide 25mg

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
IlDong Pharmaceutical Co Ltd

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	t1/2		Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]
Other	CL/F		Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]
Primary	AUClast		Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]
Primary	Cmax		Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]
Secondary	AUCinf		Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]
Secondary	Tmax		Hour 0 (Pre-dose), Hour 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144(Total 19 points)]